Avidite Base Chemistry (ABC)
Proprietary sequencing chemistry leveraging unique avidites for highly accurate, efficient data generation
Other · EmbeddedCompany source
Company profile
About Element Biosciences
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets.
Company description Element Biosciences official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Work at Element Biosciences?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- cell-free DNA analysis
- genetic variants
- somatic detection
Who it serves
- Academic labs
- AgBio
- Cancer research centers
- Clinical research
- Pharma
- Research institutions
Deployment & integration
Cloud Saas · Embedded · On Premise · Other deployment with recorded integration context.
Geographic context
MarketsGlobal (implied by service provider network) · United States
Company sourceOfficial website
Company milestones
Platform expansion
Announced upsized Series E funding June 2026; Achieved ISO 13485 certification June 2026; Introduced VITARI high-throughput platform 2026; Launched AVITI24 multiomics platform 2026; Responded to 10x Genomics patent infringement complaint May 2026
Partnerships
Recorded partners
- 10x Genomics
- Gencove
- Google Health Genomics
- Jumpcode Genomics
- The Broad Institute
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AVITI
Cost-effective, high-quality mid-throughput sequencing platform with flexible run configurations
Platform · On PremiseCompany source
AVITI LT
Low-throughput sequencing platform bringing high-quality ABC sequencing to more users at lower instrument cost
Platform · On PremiseCompany source
AVITI24
Integrated 5D multiomics platform for spatial, single-cell analysis with RNA, protein, and morphology detection
Platform · On PremiseCompany source
Cloudbreak Sequencing Kits
Sequencing reagent kits featuring Cloudbreak Freestyle and UltraQ technologies for flexible, high-quality runs
Other · OtherCompany source
ElemBio Catalyst
Technology access program for Element Biosciences platforms and solutions
Service · OtherCompany source
ElemBio Cloud
Cloud-based data analysis and visualization platform for Element sequencing data
Software · Cloud SaaSCompany source
Teton CytoProfiling Kits
Direct in-sample multiomics kits for spatial, single-cell analysis without library prep
Other · OtherCompany source
Trinity Sequencing Kits
Sequencing reagent kits for Element Biosciences platforms
Other · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Characterization of subclonal variants in HG002 Genome in a Bottle reference material as a resource for benchmarking variant callers.Cell genomics · Apr 8, 2026
Complete genomes of a multi-generational pedigree to expand studies of genetic and epigenetic inheritance.bioRxiv : the preprint server for biology · Dec 16, 2025
A rapid and dynamic role for FMRP in the plasticity of adult neurons.Nature communications · Nov 23, 2025
The ICGC ARGO data dictionary for standardizing global cancer clinical data.Scientific data · Nov 20, 2025
A simplified hybrid capture approach retains high specificity and enables PCR-free workflow.BMC genomics · Sep 2, 2025
Correction: Development and extensive sequencing of a broadly-consented Genome in a Bottle matched tumor-normal pair.Scientific data · Aug 8, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
>90% Q30 quality
Base calling quality across platforms
>70% Q50+ with Cloudbreak UltraQ
Ultra-high quality sequencing
$100 genome
VITARI platform cost efficiency
50% greater sequencing output
AVITI24 vs AVITI
<24 hour run times
Multiomics profiling on AVITI24
Up to 2 million adherent cells profiled
AVITI24 spatial multiomics capacity
20 cm² imaging area
AVITI24 spatial coverage
10x Genomics
Single cell analysis meeting Certified Partner Program requirements
AVITI System easily achieved CPP requirements for single cell analysis, expanding customer options for accessing the technology
Gencove
Sequencing challenging sample types including FFPE samples
AVITI System outperformed reference sequencer with higher effective genome coverage, especially on FFPE samples
Google Health Genomics
Human reference genome sequencing with improved error rates in difficult contexts
Cleanness in Element data from reduced error rates improves analysis at low sequencing depth, especially relevant for somatic detection, cell-free DNA, and low-pass calling
Jumpcode Genomics
Sequencing quality comparison across platforms for genomic analysis
Measurably higher percent unique alignment to hg38 and significantly lower percent duplication rate compared to other sequencing platforms
The Broad Institute
Installation and deployment of 3 AVITI systems for genomics research
Fastest and easiest installation experienced, most seamless process with quickest time from uncrating to first data set
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Molly He
CEO
Matthew Kellinger
Co-Founder
Michael Previte
CTO, SVP R&D, Co-founder
Joe Dierdorf
Vice President, Corporate Controller
Logan Zinser, CPA
Chief Financial Officer (CFO)
David Melaugh
General Counsel, Corporate Secretary
AmirAli Kia
VP, Artificial Intelligence and Data Science
Claudia J.
VP, Software
06 · Company updates
Updates from Element Biosciences
Recent articles published on Element Biosciences's official website.
What ISO 13485 Certification Means for Clinical Sequencing Labs
Read on Element BiosciencesSNP arrays vs. genotyping-by-sequencing: A technical comparison for livestock breeding programs
Read on Element BiosciencesMeasuring what actually matters: the quest for unbiased sequencing benchmarks
Read on Element BiosciencesWhy the NGI at SciLifeLab chose AVITI24™ and what they’ve discovered since
Read on Element BiosciencesNGS for MRD Detection: Sensitivity Requirements and Platform Comparison
Read on Element Biosciences07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.